
Asimov provides scientists and manufacturers tools that simplify designing and manufacturing biologic drugs and gene therapies. The company combines mammalian synthetic biology with computer-aided…

Asimov provides scientists and manufacturers tools that simplify designing and manufacturing biologic drugs and gene therapies. The company combines mammalian synthetic biology with computer-aided…
Headquarters & focus: Boston-based synthetic biology company building CAD-style platform for biologic, cell, gene, and RNA therapeutic design
Product: Integrated platform of engineered host cell lines, validated genetic parts, and cloud-based design software (CHO Edge, LV Edge, AAV Edge, RNA Edge)
Founding: Founded in 2017 by Alec Nielsen, Christopher Voigt, Douglas Densmore, and Raja Srinivas
Funding: Reported total funding approximately $205M, including a reported $200M round announced Jan 2023
Employees: Approximately 106 employees
Design and manufacturing tooling for next-generation biologics, cell, gene, and RNA therapies.
2017
Biotechnology Research
4700000
Reported seed financing at company launch
200000000
Reported large institutional financing announced Jan 2023
“AME Cloud Ventures, Andreessen Horowitz, CPP Investments, Casdin Capital, DCVC, Fidelity, Horizons Ventures, KdT Ventures, Pillar VC”
| Company |
|---|
Our mission at Asimov is to advance humanity's ability to design living systems, enabling biotechnologies with outsized benefit to society. We've built a mammalian synthetic biology platform – from cells to software – to enable the design and manufacture of next-generation therapeutics.
We are seeking a Head of Cell Line Development (CLD) to lead Asimov’s biologics CLD team and help push the boundaries of biologics manufacturing. The successful candidate will be responsible for managing direct reports and lab activities in support of the generation and characterization of cell lines expressing the highest quantity and quality of protein therapeutics. We have experienced rapid growth in both our project portfolio and CLD team, and we expect that growth trajectory to continue for the foreseeable future. This role will be central to scaling capabilities, workflows, and leadership structures accordingly.
This role requires a strategic leader with a deep technical foundation in biologics cell line development and a proven track record of growing and managing high-performing teams. Working closely with Asimov’s synthetic biology, process development, computational modeling, and software teams, this role will shape Asimov’s CLD vision and contribute as a thought leader to advance the state of the art in biologics cell line development. The role will also partner with commercial, program management, and technical teams to support customer-facing communications, including scientific discussions with prospective clients and collaborators. This is a unique opportunity to work at a nimble, forward-thinking synthetic biology company.
About The Role
About You
We're fueled by a vision to transform biological engineering into a fully-fledged engineering discipline. Should you join our team, you will grow with a constantly evolving organization and push the frontiers of synthetic biology. Company culture is key to Asimov, and ours is a culture of recombination; we believe that our mission can only be achieved by bringing together a diverse team with a mixture of backgrounds and perspectives.
Compensation Range: $220K - $280K
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
65,000+
Open Roles
1,400+
New This Week